Heat Biologics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
April 26 2017 - 7:00AM
Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a
leader in the development of immunotherapies designed to activate a
patient’s immune system against cancer, announced today that Jeff
Wolf, Heat’s Founder and CEO, will present at PIONEERS 2017,
presented by Joseph Gunnar & Co., on Tuesday, May 2, 2017, at
11:30 a.m. ET. The event will be held at the Mandarin
Oriental Hotel in New York City.
Management will be available to meet with investors during the
conference. For more information about the conference or to
schedule a one-on-one meeting with management, please contact your
Joseph Gunnar & Co. representative, email
conference@jgunnar.com or email investorrelations@heatbio.com.
About Heat Biologics, Inc.Heat Biologics, Inc.
(Nasdaq:HTBX) is an immuno-oncology company developing novel
therapies that are designed to activate a patient’s immune system
against cancer utilizing an engineered form of gp96, a protein that
robustly activates the immune system. Heat’s highly specific T
cell-stimulating therapeutic vaccine platform technologies, ImPACT
and ComPACT, in combination with other therapies, such as
checkpoint inhibitors, are designed to address three distinct but
synergistic mechanisms of action: robust activation of CD8+
“killer” T cells (one of the human immune system’s most potent
weapons against cancer); reversal of tumor-induced immune
suppression; and T cell co-stimulation to further enhance patients’
immune response. Currently, Heat is conducting a Phase 2
trial with HS-110 (viagenpumatucel-L) in combination with an
anti-PD-1 checkpoint inhibitor to treat patients with non-small
cell lung cancer (NSCLC) and a Phase 2 trial with HS-410
(vesigenurtacel-L) in patients with non-muscle invasive bladder
cancer (NMIBC).
Heat’s wholly-owned subsidiary, Zolovax, Inc., is developing
therapeutic and preventative vaccines to treat infectious diseases
based on Heat’s gp96 vaccine technology, with a current focus on
the development of a Zika vaccine in conjunction with the
University of Miami.
For more information, please visit www.heatbio.com.
For Investor Inquiries:
David Waldman
919-240-7133
Investorrelations@heatbio.com
For Media Inquiries:
Deanne Eagle
Planet Communications
917-837-5866
deanne@planetcommunications.nyc
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Apr 2023 to Apr 2024